Literature DB >> 34224581

Undisclosed HIV status and antiretroviral therapy use among South African blood donors.

Karin van den Berg1,2,3, Marion Vermeulen3,4, Vernon J Louw2, Edward L Murphy5,6, Gary Maartens7.   

Abstract

BACKGROUND: Undisclosed antiretroviral drug (ARV) use among blood donors who tested HIV antibody positive, but RNA negative, was previously described by our group. Undisclosed ARV use represents a risk to blood transfusion safety. We assessed the prevalence of and associations with undisclosed ARV use among HIV-positive donors who donated during 2017. STUDY DESIGN AND METHODS: South African National Blood Service (SANBS) blood donors are screened by self-administered questionnaire, semi-structured interview, and individual donation nucleic acid amplification testing for HIV. Stored samples from HIV-positive donations were tested for ARV and characterized as recent/longstanding using lag avidity testing.
RESULTS: Of the 1462 HIV-positive donations in 2017, 1250 had plasma availability for testing of which 122 (9.8%) tested positive for ARV. Undisclosed ARV use did not differ by gender (p = .205) or ethnicity (p = .505) but did differ by age category (p < .0001), donor (p < .0001), clinic type (p = .012), home province (p = .01), and recency (p < .0001). Multivariable logistic regression found older age (adjusted odds ratio [aOR] 3.73, 95% confidence interval [CI] 1.98-7.04 for donors >40 compared with those <21), first-time donation (aOR 5.24; 95% CI 2.48-11.11), and donation in a high HIV-prevalence province (aOR 9.10; 95% CI 2.70-30.72) compared with Northern Rural provinces to be independently associated with undisclosed ARV use. DISCUSSION: Almost 1 in 10 HIV-positive blood donors neglected to disclose their HIV status and ARV use. Demographic characteristics of donors with undisclosed ARV use differed from those noted in other study. Underlying motivations for nondisclosure among blood donors remain unclear and may differ from those in other populations with significant undisclosed ARV use.
© 2021 AABB.

Entities:  

Keywords:  HIV; South Africa; anti-retroviral agents; blood donors; disclosure; prevalence

Mesh:

Year:  2021        PMID: 34224581      PMCID: PMC8355170          DOI: 10.1111/trf.16571

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.337


  25 in total

1.  Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052).

Authors:  Jessica M Fogel; Lei Wang; Teresa L Parsons; San-San Ou; Estelle Piwowar-Manning; Ying Chen; Victor O Mudhune; Mina C Hosseinipour; Johnstone Kumwenda; James G Hakim; Suwat Chariyalertsak; Ravindre Panchia; Ian Sanne; Nagalingeswaran Kumarasamy; Beatriz Grinsztejn; Joseph Makhema; Jose Pilotto; Breno R Santos; Kenneth H Mayer; Marybeth McCauley; Theresa Gamble; Namandjé N Bumpus; Craig W Hendrix; Myron S Cohen; Susan H Eshleman
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

Review 2.  An overview of the antiretroviral market.

Authors:  Geannan Camponeschi; Jessica Fast; Marianne Gauval; Katherine Guerra; Meredith Moore; Siddharth Ravinutala; David Ripin; Vadim Shepel
Journal:  Curr Opin HIV AIDS       Date:  2013-11       Impact factor: 4.283

3.  Undetectable does not equal untransmittable for HIV and blood transfusion.

Authors:  Iain B Gosbell; Veronica C Hoad; Claire E Styles; June Lee; Clive R Seed
Journal:  Vox Sang       Date:  2019-05-20       Impact factor: 2.144

4.  Assessment of HIV transfusion transmission risk in South Africa: a 10-year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes.

Authors:  Marion Vermeulen; Nico Lelie; Charl Coleman; Wendy Sykes; Genevieve Jacobs; Ronel Swanevelder; Michael Busch; Gert van Zyl; Eduard Grebe; Alex Welte; Ravi Reddy
Journal:  Transfusion       Date:  2018-09-28       Impact factor: 3.157

5.  Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test.

Authors:  Linda L Jagodzinski; Mark M Manak; Holly R Hack; Ying Liu; Jennifer A Malia; Joanna Freeman; Nittaya Phanuphak; Mark de Souza; Eugène D Kroon; Donn J Colby; Nitiya Chomchey; Michelle A Lally; Nelson L Michael; Jintanat Ananworanich; Sheila A Peel
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

6.  Motivators and deterrents to blood donation among Black South Africans: a qualitative analysis of focus group data.

Authors:  T N Muthivhi; M G Olmsted; H Park; M Sha; V Raju; T Mokoena; E M Bloch; E L Murphy; R Reddy
Journal:  Transfus Med       Date:  2015-06-23       Impact factor: 2.019

7.  Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection.

Authors:  Mark M Manak; Linda L Jagodzinski; Ashley Shutt; Jennifer A Malia; Mike Leos; Jason Ouellette; Siriwat Akapirat; Donn L Colby; Nittaya Phanuphak; Leigh Anne Eller; Merlin L Robb; Mark de Souza; Jintanat Ananworanich; Sheila A Peel
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

8.  Undisclosed HIV infection among MSM in a behavioral surveillance study.

Authors:  Brooke E Hoots; Cyprian Wejnert; Amy Martin; Richard Haaland; Silvina Masciotra; Catlainn Sionean; Amanda Smith; William M Switzer; Gabriela Paz-Bailey
Journal:  AIDS       Date:  2019-04-01       Impact factor: 4.177

9.  Adult antiretroviral therapy guidelines 2017.

Authors:  Graeme Meintjes; Michelle A Moorhouse; Sergio Carmona; Natasha Davies; Sipho Dlamini; Cloete van Vuuren; Thandekile Manzini; Moeketsi Mathe; Yunus Moosa; Jennifer Nash; Jeremy Nel; Yoliswa Pakade; Joana Woods; Gert Van Zyl; Francesca Conradie; Francois Venter
Journal:  South Afr J HIV Med       Date:  2017-07-15       Impact factor: 2.744

10.  Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection.

Authors:  Oliver Laeyendecker; Jacob Konikoff; Douglas E Morrison; Ronald Brookmeyer; Jing Wang; Connie Celum; Charles S Morrison; Quarraisha Abdool Karim; Audrey E Pettifor; Susan H Eshleman
Journal:  J Int AIDS Soc       Date:  2018-02       Impact factor: 5.396

View more
  1 in total

1.  The Impact of Early Antiretroviral Treatment (ART) for HIV on the Sensitivity of the Latest Generation of Blood Screening and Point of Care Assays.

Authors:  Marion Vermeulen; Cari van Schalkwyk; Genevieve Jacobs; Karin van den Berg; Mars Stone; Sonia Bakkour; Brian Custer; Ute Jentsch; Michael P Busch; Edward Murphy; Eduard Grebe
Journal:  Viruses       Date:  2022-06-29       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.